Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors
  • Library

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, China
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Our sub-categories
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2025
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Galderma Insights
    • Podcasts
  • Innovation
    • Bringing innovation to life
    • Partnerships
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Investors
  • Library
You searched for: «sculptra»
Results 16 - 20 of 111
Page 4 of 23
  1. Media
  2. Newsroom

Galderma receives FDA approval for Sculptra® for cheek wrinkles

  • Sculptra® helps improve skin quality and results can last up to 2 years1-2

 

  • The first and original PLLA collagen stimulator is now approved for the correction of fine lines and wrinkles in the full cheek area3-4

 

  1. Media
  2. Newsroom

Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets

  • Sculptra®, the first proven regenerative biostimulator, will provide new options for patients in China who are looking for innovative treatments to correct mid-facial volume loss and/or contour deficiencies1-7 

  1. Media
  2. Newsroom

Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners

  • New label update allows for immediate use after reconstitution and more convenient administration of SCULPTRA® with the optional addition of lidocaine for increased patient comfort

 

  1. Media
  2. Newsroom

AMWC 2023: Data from Sculptra® Cheek Wrinkle and Alluzience® Star Studies reinforce strength of Galderma’s broad aesthetic portfolio

  • Galderma will present results from the innovative Sculptra® Cheek Wrinkle study, which demonstrate the long-lasting results over a 24-month period of the treatment for cheek wrinkle correction with significant improvements in skin firmness and radiance[1]

  1. Media
  2. Newsroom

Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss

  • Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra® and Restylane® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss1
  • Following interim analysis at three months pres
Results 16 - 20 of 111
Page 4 of 23

Pagination

  • Previous page Previous Page
  • Next page Next Page
  1. Home
  2. Search results

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2026

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back